Kidney Cancer Clinical Trial

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Summary

To evaluate the combination of PF-04856884 (CVX-060) in combination with Axitinib (AG-013736) in patients that have received one prior systemic regimen for metastatic renal cell carcinoma (mRCC) vs. axitinib alone.

View Full Description

Full Description

The study was prematurely discontinued on 06Nov2012 due to tolerability findings in patients treated in Part I of the study that have prompted the Sponsor to re-evaluate the strategic development of the program. An unexpected frequency of arterial thrombotic events (ATEs) and venous thrombotic events (VTEs) were reported in patients treated in Part I.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adult male or female patients with histologically or cytologically confirmed renal cell cancer (RCC) with a component of clear cell subtype and evidence of metastasis
Evidence of unidimensionally measurable disease
Prior therapy: Part I: Having received 1 to 3 prior systemic regimens for treatment of mRCC
Part II: Evidence of disease progression following 1 prior regimen administered as 1st line therapy for mRCC. The prior regimen must have contained one of the following: VEGFR2 tyrosine kinase inhibitor (TKI) or other anti VEGF [Vascular Endothelial Growth Factor] compounds, such as bevacizumab
adequate bone marrow, liver and renal function

Exclusion Criteria:

Part I:

Intolerant to prior AG 013736 therapy or prior treatment with compounds which contain the core platform antibody as PF 04856884

Part II:

Prior AG 013736 therapy, more than one systemic first-line regimen for the treatment of mRCC and prior treatment with compounds which contain the core platform antibody as PF 04856884
major surgery <4 weeks or radiation therapy <2 weeks prior to start of therapy
clinically significant gastrointestinal abnormalities
current use or anticipated need for drugs that are known potent CYP3A4 inhibitors and drugs that are known CYP3A4 or CYP1A2 inducers
history of bleeding diathesis or coagulopathy
Grade 3 or greater hemorrhage from any cause <4 weeks prior to screening;
hemoptysis >½ teaspoon of blood per day within 2 weeks prior to screening.

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

18

Study ID:

NCT01441414

Recruitment Status:

Terminated

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 29 Locations for this study

See Locations Near You

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

18

Study ID:

NCT01441414

Recruitment Status:

Terminated

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider